Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats acute myeloid leukemia (AML) Reduce the duration of neutropenia and…. Sold as Filkri. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Filgrastim-Laha (sold as Filkri), first approved Jan 15, 2026, with 0 new uses approved and 1 published complete response letter.
GranDrugs with a new indication and a new dosage for use as an adjunctive therapy with antineoplastic agents for the treatment of relapsed or refractory acute… · Kyowa Kirin Co., Ltd. · Jun 20, 2022
GranDrugs with a new indication and a new dosage for the enhancement of an antitumor effect of dinutuximab (genetical recombination) for neuroblastoma. · Kyowa Kirin Co., Ltd. · Jun 23, 2021
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
